ATE359789T1 - Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen - Google Patents

Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Info

Publication number
ATE359789T1
ATE359789T1 AT03798175T AT03798175T ATE359789T1 AT E359789 T1 ATE359789 T1 AT E359789T1 AT 03798175 T AT03798175 T AT 03798175T AT 03798175 T AT03798175 T AT 03798175T AT E359789 T1 ATE359789 T1 AT E359789T1
Authority
AT
Austria
Prior art keywords
medication
treatment
production
myelodysplastic syndrome
phthalazine derivatives
Prior art date
Application number
AT03798175T
Other languages
German (de)
English (en)
Inventor
Margaret Han Dugan
Alan List
Original Assignee
Novartis Pharma Gmbh
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh, Univ Arizona filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE359789T1 publication Critical patent/ATE359789T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03798175T 2002-09-24 2003-09-23 Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen ATE359789T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24

Publications (1)

Publication Number Publication Date
ATE359789T1 true ATE359789T1 (de) 2007-05-15

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03798175T ATE359789T1 (de) 2002-09-24 2003-09-23 Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Country Status (22)

Country Link
US (1) US20060128716A1 (enExample)
EP (1) EP1545534B1 (enExample)
JP (1) JP2006502195A (enExample)
KR (1) KR20050074450A (enExample)
CN (1) CN100372535C (enExample)
AT (1) ATE359789T1 (enExample)
AU (1) AU2003299065B2 (enExample)
BR (1) BR0314647A (enExample)
CA (1) CA2499738A1 (enExample)
CR (1) CR7754A (enExample)
DE (1) DE60313344T2 (enExample)
EC (1) ECSP055700A (enExample)
ES (1) ES2285251T3 (enExample)
HR (1) HRP20050281A2 (enExample)
MX (1) MXPA05003161A (enExample)
NO (1) NO20051936L (enExample)
PL (1) PL374696A1 (enExample)
PT (1) PT1545534E (enExample)
RS (1) RS20050228A (enExample)
RU (1) RU2353364C2 (enExample)
WO (1) WO2004028542A1 (enExample)
ZA (1) ZA200502212B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors

Also Published As

Publication number Publication date
AU2003299065B2 (en) 2006-10-26
JP2006502195A (ja) 2006-01-19
US20060128716A1 (en) 2006-06-15
ECSP055700A (es) 2005-08-11
CN1684684A (zh) 2005-10-19
NO20051936L (no) 2005-06-23
RU2005112711A (ru) 2006-02-27
CR7754A (es) 2005-12-02
DE60313344D1 (de) 2007-05-31
PL374696A1 (en) 2005-10-31
WO2004028542A1 (en) 2004-04-08
ZA200502212B (en) 2006-02-22
CN100372535C (zh) 2008-03-05
ES2285251T3 (es) 2007-11-16
DE60313344T2 (de) 2008-01-03
CA2499738A1 (en) 2004-04-08
HRP20050281A2 (en) 2006-07-31
BR0314647A (pt) 2005-08-02
EP1545534A1 (en) 2005-06-29
MXPA05003161A (es) 2005-09-12
EP1545534B1 (en) 2007-04-18
KR20050074450A (ko) 2005-07-18
RS20050228A (sr) 2007-08-03
AU2003299065A1 (en) 2004-04-19
RU2353364C2 (ru) 2009-04-27
PT1545534E (pt) 2007-06-22

Similar Documents

Publication Publication Date Title
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20045056L (no) Fremgangsmater for behandling av hepatitt
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
SE0301886D0 (sv) New use V
SE0301882D0 (sv) New use I
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE511835T1 (de) Biophosphonate zur behandlung von endometriose
ATE339202T1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE363923T1 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
ATE359789T1 (de) Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
SE0301885D0 (sv) New use IV
SE0301884D0 (sv) New use III
BR0112123A (pt) Composto
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1545534

Country of ref document: EP

REN Ceased due to non-payment of the annual fee